Latest Hypnotics Stories
Nearly one-in-four U.S workers are affected by insomnia, costing the nation $63.2 billion a year in lost productivity.
Study Finds Prescription Drug Overdoses Eclipse Those from Heroin and Cocaine Beverly Hills, CA (PRWEB) August 01, 2011 According to a report from the Centers for Disease Control and Prevention (CDC) and reported by Bloomberg, the death rate of overdoses from prescription drugs in Florida have more than doubled in the past ten years.
SAN DIEGO, July 28, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended June 30, 2011.
POINT RICHMOND, Calif., July 15, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today plans to reduce operating expenses by eliminating approximately 45% of its workforce following notification from the U.S.
POINT RICHMOND, Calif., July 14, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that it has received a Complete Response Letter from the U.S.
POINT RICHMOND, Calif., July 12, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that it expects to receive a Complete Response Letter from the U.S.
ANAHEIM, Calif., July 7, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release second quarter 2011 financial results on Tuesday, July 26, 2011 after the close of the U.S. financial markets.
EXTON, Pa., June 24, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for BuccolamÂ® (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years.
BETHLEHEM, Pa., June 22, 2011 /PRNewswire/ -- In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam (NRL-1) achieved positive clinical results in a Phase I pharmacokinetic study. The propriety formulation was designed and manufactured at Particle Sciences.